Results 151 to 160 of about 2,423,182 (300)

Tackling cancer stemness with nanotechnology in the era of precision medicine

BMEMat, EarlyView.
Precise customization of nanoparticles (NPs) enables active targeting of cancer stem cells (CSCs), thereby improving drug delivery and therapeutic efficacy. NP‐based probing enhances CSC detection through imaging and liquid biopsy, whereas diverse therapeutic payloads improve therapeutic outcomes.
Shaolei Guo, Shun Yao, Lihui Meng, Chunyuan Chen, Yuechu Lucinda Lu, Rong Lu, Kashif Rafiq Zahid, Umar Raza, Qingzhi Wu, Wenli Chen   +9 more
wiley   +1 more source

Tailoring drug‐to‐lipid ratio in redox‐responsive lipid‐mimetic prodrug liposomes for superior cabazitaxel delivery and antitumor efficacy

BMEMat, EarlyView.
Redox‐responsive lipid‐mimetic prodrug liposomes with high drug‐to‐lipid ratios enhance cabazitaxel delivery, prolong circulation, and enable tumor‐selective drug release for superior antitumor efficacy and safety. Abstract Liposomes represent one of the most extensively investigated nanocarriers in drug delivery.
Shengyao Xu, Danping Wang, Si Zheng, Zhiyu Kuang, Ya Gao, Haiyu Zhao, Lurong Zhang, Jiayu Guo, Jingyi Zhang, Weiyao Li, Anhua Wang, Hongrui Lei, Zhonggui He, Ken‐ichiro Kamei, Jianzhao Niu, Lingyun Ma, Bingjun Sun   +16 more
wiley   +1 more source

Drug hypersensitivity.

Nihon Naika Gakkai Zasshi, 1994
openaire   +3 more sources

Engineering programmable peptide hydrogels for chronic refractory wounds: A mechanism‐driven framework

BMEMat, EarlyView.
To break the self‐perpetuating pathology of chronic wounds, we propose a mechanism‐driven engineering framework for peptide‐based hydrogels. This review elucidates a hierarchical strategy—from molecular design to intelligent, multi‐functional systems—that enables these programmable biomaterials to dynamically intervene in key pathological loops and ...
Xiaoyu Lv, Xinyi Chao, Jiamin Zhang, Jianfeng Liu   +3 more
wiley   +1 more source

In vitro diagnostics of drug hypersensitivity reactions. [PDF]

Allergol Select
Möbs C, Hermann Lang SC, Härtel V, Pfützner W.   +3 more
europepmc   +1 more source

Ten‐year follow‐up of bilateral gingival recession treatment: A case report

Clinical Advances in Periodontics, EarlyView.
Abstract Background This work aims to present a 10‐year follow‐up of a young patient who underwent treatment with collagen matrix (CM) combined with enamel matrix derivative (EMD) for bilateral gingival recessions in the maxillary canine region. Methods The patient, a 25‐year‐old woman, presented with bilateral Cairo type 1 recessions.
Luiz C. L. Marques‐Junior, Milena S. Irie, Edgar Daniel Vargas‐Quiroga, Mario Taba‐Jr, Atila V. V. Nobre   +4 more
wiley   +1 more source

Delayed Drug Hypersensitivity: Mechanistic Advances and Emerging Therapies. [PDF]

Curr Allergy Asthma Rep
Siddiqui A, Chow TG, Runyon LM, Phillips EJ, Alvarez-Arango S.   +4 more
europepmc   +1 more source

Highlights of the 4th Drug Hypersensitivity Meeting--Rome, April 22-25, 2010

, 2011
Drug hypersensitivity is a difficult problem, but recent advances in the genetics and understanding of the immune mechanisms of various drug hypersensitivity reactions have enabled the field to make significant progress.
Romano, Antonino
core  

Diagnostic Agreement and Threshold Correspondence Between Resting Full‐Cycle Ratio and Nicorandil‐Based Fractional Flow Reserve in Intermediate Coronary Stenosis: A Prospective Single‐Center Registry

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background RFR has shown good aggregate agreement with FFR, including in prior Asian cohorts using intracoronary nicorandil. Where RFR‐FFR disagreement is concentrated relative to the FFR 0.80 decision boundary, and how the two binary thresholds correspond, remain incompletely characterized. Methods In a prospective single‐center registry, 300
Yonghoon Shin, Onyou Kim, Gi Won Yu, Yun Won Lee, Jung‐Joon Cha, Hyung Joon Joo, Jae Hyoung Park, Soon Jun Hong, Cheol Woong Yu   +8 more
wiley   +1 more source

Editorial: Pharmacogenomics of drug hypersensitivity reactions. [PDF]

Front Pharmacol
Kassogue Y, Fricke-Galindo I.
europepmc   +1 more source